Found 1803 clinical trials
Predictors of Recurrence for High Risk Endometrial Cancer Patients
This study will analyze whether there is any difference in recurrence and survival rates among the patients who received different adjuvant therapies.
- 0 views
- 16 Feb, 2024
- 1 location
Blood Biomarker of Alzheimer's Disease (AD)
Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations.
- 0 views
- 16 Feb, 2024
- 1 location
Advanced Translational Research on Childhood Leukemia
Yet, relapse still occurs in 15-40% of patients with a probability of survival of <50%, which is unlikely to be boosted by intensification of standard chemotherapy due to overwhelming toxicity. The advent of effective and safe targeted therapies for high-risk cases is therefore imperative. This study constitutes two research projects …
- 0 views
- 05 Aug, 2020
Tissue Models for Liver Disease (TIMOLD)
Primary Objectives: The primary objective of the study is to identify therapies acting on the initial events during invasive bacterial and viral infection. Secondary Objectives: The secondary objective of this study is to provide novel in vitro and ex vivo models of human liver macrophages to study the impact of …
- 0 views
- 24 May, 2022
- 1 location
Health Economy Register
In breast oncology, the increasing number of oral and intravenous drug therapies pose great challenges for patient management. Numerous studies demonstrate that well-informed patients develop higher confidence in their treatment and a greater sense of disease control, resulting in increased adherence and persistence as well as potentially better outcome.
- 0 views
- 16 Feb, 2024
- 10 locations
Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology
It will provide insight into real-world biomarker-directed treatment of cancer patients not eligible for standard therapies. The study will retrospectively collect medical records' data of patients who received a targeted treatment based on a potentially actionable alteration or biomarker identified by molecular diagnostics.
- 0 views
- 16 Feb, 2024
- 1 location
Bringing of PET-TDM FDG in the Determination of the Characteristics of Primary Mammary Tumors TrIple Negatives
Accurate identification of prognostic factors, as well as predictors of therapeutic response, and the contribution of targeted therapies are avenues for improving the management and survival of patients with these cancers. Such an approach requires optimal biological characterization, allowing us to understand the complexity of this group of tumors, and …
- 0 views
- 16 Feb, 2024
- 1 location
Off-label Use of Anti-cancer Drugs in Norway -a Prospective Cohort Study
The number of drugs suitable for off-label use is expected to further increase in the coming years, owing to the rapid progress in the field of oncology, in particular with the current era of precision medicine and targeted therapies. This also challenges the traditional method of running clinical trials, with …
- 0 views
- 05 Aug, 2020
HFNC and NIV for COVID-19 Complicated by Respiratory Failure
High flow nasal cannula (HFNC) oxygen therapy and noninvasive ventilation (NIV) may offer respiratory support to patients with COVID-19 complicated by acute hypoxemic respiratory failure if conventional oxygen therapy (COT) fails to maintain satisfactory oxygenation but whether these respiratory therapies would lead to airborne viral transmission is unknown. Aims: This …
- 0 views
- 16 Feb, 2024
- 1 location
Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer
The intensive study of predictive factors has strongly ameliorated the therapeutic flow-chart of metastatic colorectal cancer (mCRC) by allowing the selection of patients who benefit from specific therapies. In this context, the assessment of RAS (N- and K-) oncogene mutations is able to predict the response to anti-EGFR agents being …
- 0 views
- 16 Feb, 2024
- 1 location